Raludotatug deruxtecan shows 50.5% response rate in ovarian cancer trial

Daiichi Sankyo (TSE:4568) and Merck (NYSE:MRK) reported positive Phase 2 results for their investigational CDH6-directed antibody drug conjugate, Raludotatug deruxtecan (R-DXd), in recurrent platinum-resistant ovarian cancer, achieving a 50.5% objective response rate. The 5.6 mg/kg dose, selected for Phase 3, demonstrated a 50.0% ORR and 80.6% disease control rate with a manageable safety profile. These findings, which contributed to its FDA Breakthrough Therapy Designation, position R-DXd as a promising therapeutic candidate for a challenging patient population, with Phase 3 trials slated to compare it against standard chemotherapy.

Analysis

Daiichi Sankyo (TSE:4568) and Merck (NYSE:MRK) reported compelling Phase 2 results for Raludotatug deruxtecan (R-DXd) in platinum-resistant ovarian cancer, achieving a 50.5% objective response rate (ORR) across all doses. The 5.6 mg/kg dose, selected for Phase 3, demonstrated a 50.0% ORR and an 80.6% disease control rate (DCR) in a challenging patient population with prior therapies. This data supports the drug's potential in an area of high unmet medical need.

The safety profile for R-DXd was consistent with prior findings, with no treatment discontinuations due to adverse events at the 5.6 mg/kg dose, indicating good tolerability. The FDA's Breakthrough Therapy Designation for R-DXd underscores its perceived clinical significance and potential to address serious conditions. This regulatory fast-track could accelerate its path to market, enhancing its commercial prospects.

Beyond R-DXd, Daiichi Sankyo and AstraZeneca (AZN) showcased robust pipeline advancements, including ENHERTU's significant improvements in pCR and invasive disease-free survival for HER2+ breast cancer. AstraZeneca's Datroway also met primary endpoints in metastatic triple-negative breast cancer, highlighting a strong portfolio of oncology assets. These collective developments suggest sustained innovation and potential for future revenue streams across both companies.

Key Decisions for Investors

• Monitor the progression of R-DXd into Phase 3 trials and subsequent regulatory milestones for Daiichi Sankyo and Merck, as successful outcomes could significantly impact their oncology franchises.
• Evaluate the broader oncology pipelines of Daiichi Sankyo and AstraZeneca, particularly the continued strong performance of ENHERTU and Datroway, which signal potential for sustained market leadership and revenue growth.
• Consider the implications of FDA Breakthrough Therapy Designation for R-DXd, which may indicate a faster development and approval timeline, potentially accelerating market entry and revenue generation.